Neuronetics (NASDAQ: STIM) ex-officer lines up $464K stock sale

Rhea-AI Filing Summary

Neuronetics, Inc. (STIM) disclosed that former officer William A. Macan has filed to sell shares of the company’s common stock under Rule 144. The notice covers up to 149,891 shares, valued at approximately $463,934.30, with sales expected through NASDAQ. These shares were acquired on 08/14/2026 via restricted stock vesting as compensation from the issuer. In the preceding three months, Macan sold 121,033 shares for about $388,273.87.

Key Figures

Shares proposed for sale: 149,891 shares Aggregate market value of shares proposed: $463,934.30 Shares sold in prior 3 months: 121,033 shares +3 more

6 metrics

Shares proposed for sale 149,891 shares Common stock covered by the Rule 144 notice

Aggregate market value of shares proposed $463,934.30 Value of 149,891 shares referenced in the notice

Shares sold in prior 3 months 121,033 shares Common stock sale reported on 08/18/2026

Value of prior 3‑month sales $388,273.87 Proceeds from 121,033 shares sold on 08/18/2026

Acquisition date of restricted stock 08/14/2026 Date shares were acquired via Restricted Stock Vesting as compensation

Planned sale method NASDAQ Exchange identified for potential sales of common stock

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact, Former Officer

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 08/14/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as attorney-in-fact for William Macan"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Former Officer other

"Former Officer 144: Securities Information"

FAQ

What does the Form 144 filing mean for Neuronetics, Inc. (STIM)?

A former officer of Neuronetics, Inc. filed a Rule 144 notice to potentially sell 149,891 shares of STIM common stock. This indicates planned resale of previously restricted shares, not a new share issuance by the company.

How many Neuronetics (STIM) shares are covered by the planned Rule 144 sale?

The notice covers up to 149,891 shares of Neuronetics common stock. These shares were received as compensation through restricted stock vesting on 08/14/2026 before being eligible for resale.

What is the approximate value of the Neuronetics (STIM) shares registered for sale?

The planned sale under Rule 144 relates to shares valued at about $463,934.30. This value reflects the market price used in the notice and helps determine compliance with Rule 144 volume and value limits.

Who is selling Neuronetics (STIM) shares under this Rule 144 notice?

The shares are for the account of William A. Macan, a former officer of Neuronetics, Inc. Fidelity Brokerage Services LLC is identified as the broker handling the common stock covered by the notice.

What prior Neuronetics (STIM) share sales were reported for the last three months?

The notice reports that on 08/18/2026, 121,033 shares of Neuronetics common stock were sold for about $388,273.87. These sales are disclosed to show recent trading relevant to Rule 144 aggregation rules.

How were the Neuronetics (STIM) shares being sold originally acquired?

The 149,891 shares covered by the notice were acquired on 08/14/2026 through Restricted Stock Vesting from Neuronetics as compensation, making them restricted securities now eligible for Rule 144 resale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 02:13 PM Accepted by SEC EDGAR 08/19/2026 - 02:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001758584
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Neuronetics, Inc.
SEC File Number	001-38546
Address of Issuer	3222 PHOENIXVILLE PIKE MALVERN PENNSYLVANIA 19355
Phone	877-600-7555
Name of Person for Whose Account the Securities are To Be Sold	MACAN WILLIAM ANDREW
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	149891	463934.30	76197222	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2026	Restricted Stock Vesting	Issuer			149891	08/14/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William A. Macan 3222 Phoenixville Pike Malvern PA 19355	Common	08/18/2026	121033	388273.87

144: Remarks and Signature

Remarks
Date of Notice	08/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for William Macan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)